nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—L-Phenylalanine—Melphalan—breast cancer	0.439	1	CrCrCtD
Lisdexamfetamine—Lacosamide—SCN10A—breast cancer	0.00109	0.227	CrCbGaD
Lisdexamfetamine—Lacosamide—CA9—breast cancer	0.001	0.208	CrCbGaD
Lisdexamfetamine—Labetalol—CYP2D6—breast cancer	0.000436	0.0904	CrCbGaD
Lisdexamfetamine—Lisinopril—ABCB1—breast cancer	0.000404	0.0837	CrCbGaD
Lisdexamfetamine—Dextroamphetamine—CYP2D6—breast cancer	0.000327	0.0678	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2D6—breast cancer	0.000317	0.0657	CrCbGaD
Lisdexamfetamine—Selegiline—CYP3A4—breast cancer	0.000272	0.0564	CrCbGaD
Lisdexamfetamine—Amphetamine—CYP2D6—breast cancer	0.000264	0.0546	CrCbGaD
Lisdexamfetamine—Methamphetamine—CYP2D6—breast cancer	0.000244	0.0506	CrCbGaD
Lisdexamfetamine—Phenelzine—CYP3A4—breast cancer	0.00024	0.0497	CrCbGaD
Lisdexamfetamine—Tremor—Capecitabine—breast cancer	0.000231	0.000533	CcSEcCtD
Lisdexamfetamine—Dizziness—Thiotepa—breast cancer	0.00023	0.000531	CcSEcCtD
Lisdexamfetamine—Rash—Vinorelbine—breast cancer	0.00023	0.00053	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vinorelbine—breast cancer	0.00023	0.000529	CcSEcCtD
Lisdexamfetamine—Urticaria—Fluorouracil—breast cancer	0.000229	0.000527	CcSEcCtD
Lisdexamfetamine—Headache—Vinorelbine—breast cancer	0.000228	0.000526	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Fluorouracil—breast cancer	0.000228	0.000525	CcSEcCtD
Lisdexamfetamine—Selegiline—ABCB1—breast cancer	0.000226	0.0469	CrCbGaD
Lisdexamfetamine—Palpitations—Docetaxel—breast cancer	0.000225	0.000519	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—breast cancer	0.000224	0.000517	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—breast cancer	0.000223	0.000514	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—breast cancer	0.000222	0.000512	CcSEcCtD
Lisdexamfetamine—Insomnia—Paclitaxel—breast cancer	0.000222	0.000511	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Irinotecan—breast cancer	0.000222	0.000511	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Mitoxantrone—breast cancer	0.000222	0.000511	CcSEcCtD
Lisdexamfetamine—Vomiting—Thiotepa—breast cancer	0.000221	0.00051	CcSEcCtD
Lisdexamfetamine—Convulsion—Docetaxel—breast cancer	0.000221	0.000509	CcSEcCtD
Lisdexamfetamine—Hypertension—Docetaxel—breast cancer	0.00022	0.000507	CcSEcCtD
Lisdexamfetamine—Rash—Thiotepa—breast cancer	0.00022	0.000506	CcSEcCtD
Lisdexamfetamine—Dermatitis—Thiotepa—breast cancer	0.000219	0.000506	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Paclitaxel—breast cancer	0.000219	0.000504	CcSEcCtD
Lisdexamfetamine—Headache—Thiotepa—breast cancer	0.000218	0.000503	CcSEcCtD
Lisdexamfetamine—Somnolence—Paclitaxel—breast cancer	0.000218	0.000503	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—breast cancer	0.000218	0.000502	CcSEcCtD
Lisdexamfetamine—Palpitations—Capecitabine—breast cancer	0.000218	0.000502	CcSEcCtD
Lisdexamfetamine—Nausea—Vinorelbine—breast cancer	0.000217	0.000499	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Paclitaxel—breast cancer	0.000216	0.000498	CcSEcCtD
Lisdexamfetamine—Asthenia—Mitoxantrone—breast cancer	0.000216	0.000497	CcSEcCtD
Lisdexamfetamine—Asthenia—Irinotecan—breast cancer	0.000216	0.000497	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000215	0.000496	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Paclitaxel—breast cancer	0.000213	0.000491	CcSEcCtD
Lisdexamfetamine—Hypertension—Capecitabine—breast cancer	0.000213	0.000491	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Fluorouracil—breast cancer	0.000212	0.000489	CcSEcCtD
Lisdexamfetamine—Dry mouth—Docetaxel—breast cancer	0.000212	0.000489	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000212	0.000488	CcSEcCtD
Lisdexamfetamine—Fatigue—Paclitaxel—breast cancer	0.000211	0.000487	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—breast cancer	0.000211	0.000486	CcSEcCtD
Lisdexamfetamine—Asthenia—Gemcitabine—breast cancer	0.00021	0.000484	CcSEcCtD
Lisdexamfetamine—Constipation—Paclitaxel—breast cancer	0.00021	0.000483	CcSEcCtD
Lisdexamfetamine—Anxiety—Capecitabine—breast cancer	0.000209	0.000482	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000208	0.000481	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—breast cancer	0.000208	0.000479	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Docetaxel—breast cancer	0.000208	0.000479	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—breast cancer	0.000208	0.000479	CcSEcCtD
Lisdexamfetamine—Nausea—Thiotepa—breast cancer	0.000207	0.000477	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—breast cancer	0.000206	0.000476	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mitoxantrone—breast cancer	0.000206	0.000474	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Irinotecan—breast cancer	0.000206	0.000474	CcSEcCtD
Lisdexamfetamine—Dry mouth—Capecitabine—breast cancer	0.000205	0.000473	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Docetaxel—breast cancer	0.000204	0.00047	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—breast cancer	0.000203	0.000468	CcSEcCtD
Lisdexamfetamine—Tachycardia—Docetaxel—breast cancer	0.000203	0.000468	CcSEcCtD
Lisdexamfetamine—Skin disorder—Docetaxel—breast cancer	0.000202	0.000465	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—breast cancer	0.000202	0.000465	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gemcitabine—breast cancer	0.0002	0.000462	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—breast cancer	0.000199	0.00046	CcSEcCtD
Lisdexamfetamine—Dizziness—Irinotecan—breast cancer	0.000199	0.000458	CcSEcCtD
Lisdexamfetamine—Anorexia—Docetaxel—breast cancer	0.000198	0.000457	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Capecitabine—breast cancer	0.000197	0.000455	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—breast cancer	0.000197	0.000455	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—breast cancer	0.000197	0.000454	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Fluorouracil—breast cancer	0.000197	0.000454	CcSEcCtD
Lisdexamfetamine—Tachycardia—Capecitabine—breast cancer	0.000196	0.000453	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—breast cancer	0.000196	0.000451	CcSEcCtD
Lisdexamfetamine—Skin disorder—Capecitabine—breast cancer	0.000195	0.000451	CcSEcCtD
Lisdexamfetamine—Urticaria—Paclitaxel—breast cancer	0.000195	0.000449	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Capecitabine—breast cancer	0.000195	0.000448	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Paclitaxel—breast cancer	0.000194	0.000447	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—breast cancer	0.000192	0.000443	CcSEcCtD
Lisdexamfetamine—Anorexia—Capecitabine—breast cancer	0.000192	0.000442	CcSEcCtD
Lisdexamfetamine—Vomiting—Mitoxantrone—breast cancer	0.000191	0.000441	CcSEcCtD
Lisdexamfetamine—Vomiting—Irinotecan—breast cancer	0.000191	0.000441	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—breast cancer	0.00019	0.000439	CcSEcCtD
Lisdexamfetamine—Dizziness—Fluorouracil—breast cancer	0.00019	0.000439	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—breast cancer	0.00019	0.000438	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—breast cancer	0.00019	0.000438	CcSEcCtD
Lisdexamfetamine—Rash—Mitoxantrone—breast cancer	0.00019	0.000437	CcSEcCtD
Lisdexamfetamine—Rash—Irinotecan—breast cancer	0.00019	0.000437	CcSEcCtD
Lisdexamfetamine—Dermatitis—Irinotecan—breast cancer	0.000189	0.000437	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mitoxantrone—breast cancer	0.000189	0.000437	CcSEcCtD
Lisdexamfetamine—Headache—Irinotecan—breast cancer	0.000188	0.000434	CcSEcCtD
Lisdexamfetamine—Headache—Mitoxantrone—breast cancer	0.000188	0.000434	CcSEcCtD
Lisdexamfetamine—Insomnia—Docetaxel—breast cancer	0.000188	0.000433	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—breast cancer	0.000187	0.00043	CcSEcCtD
Lisdexamfetamine—Vomiting—Gemcitabine—breast cancer	0.000186	0.000429	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Docetaxel—breast cancer	0.000185	0.000427	CcSEcCtD
Lisdexamfetamine—Somnolence—Docetaxel—breast cancer	0.000185	0.000426	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—breast cancer	0.000185	0.000426	CcSEcCtD
Lisdexamfetamine—Rash—Gemcitabine—breast cancer	0.000185	0.000426	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gemcitabine—breast cancer	0.000185	0.000425	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—breast cancer	0.000184	0.000425	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—breast cancer	0.000184	0.000423	CcSEcCtD
Lisdexamfetamine—Headache—Gemcitabine—breast cancer	0.000183	0.000423	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—breast cancer	0.000183	0.000422	CcSEcCtD
Lisdexamfetamine—Vomiting—Fluorouracil—breast cancer	0.000183	0.000422	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Docetaxel—breast cancer	0.000183	0.000422	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—breast cancer	0.000183	0.000421	CcSEcCtD
Lisdexamfetamine—Insomnia—Capecitabine—breast cancer	0.000182	0.00042	CcSEcCtD
Lisdexamfetamine—Rash—Fluorouracil—breast cancer	0.000182	0.000419	CcSEcCtD
Lisdexamfetamine—Dermatitis—Fluorouracil—breast cancer	0.000181	0.000418	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Docetaxel—breast cancer	0.000181	0.000417	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Paclitaxel—breast cancer	0.000181	0.000416	CcSEcCtD
Lisdexamfetamine—Headache—Fluorouracil—breast cancer	0.00018	0.000416	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Docetaxel—breast cancer	0.000179	0.000414	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Capecitabine—breast cancer	0.000179	0.000414	CcSEcCtD
Lisdexamfetamine—Fatigue—Docetaxel—breast cancer	0.000179	0.000413	CcSEcCtD
Lisdexamfetamine—Nausea—Mitoxantrone—breast cancer	0.000179	0.000412	CcSEcCtD
Lisdexamfetamine—Nausea—Irinotecan—breast cancer	0.000179	0.000412	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—breast cancer	0.000178	0.000411	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—breast cancer	0.000178	0.00041	CcSEcCtD
Lisdexamfetamine—Constipation—Docetaxel—breast cancer	0.000178	0.00041	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Capecitabine—breast cancer	0.000177	0.000408	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—breast cancer	0.000176	0.000406	CcSEcCtD
Lisdexamfetamine—Asthenia—Paclitaxel—breast cancer	0.000176	0.000406	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Capecitabine—breast cancer	0.000175	0.000403	CcSEcCtD
Lisdexamfetamine—Nausea—Gemcitabine—breast cancer	0.000174	0.000401	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Capecitabine—breast cancer	0.000174	0.0004	CcSEcCtD
Lisdexamfetamine—Fatigue—Capecitabine—breast cancer	0.000173	0.0004	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—breast cancer	0.000173	0.000399	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—breast cancer	0.000173	0.000399	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—breast cancer	0.000173	0.000398	CcSEcCtD
Lisdexamfetamine—Constipation—Capecitabine—breast cancer	0.000172	0.000397	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—breast cancer	0.000172	0.000396	CcSEcCtD
Lisdexamfetamine—Nausea—Fluorouracil—breast cancer	0.000171	0.000394	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—breast cancer	0.000171	0.000393	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—breast cancer	0.000169	0.000391	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Paclitaxel—breast cancer	0.000168	0.000387	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—breast cancer	0.000167	0.000385	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—breast cancer	0.000165	0.00038	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—breast cancer	0.000165	0.000379	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Docetaxel—breast cancer	0.000164	0.000379	CcSEcCtD
Lisdexamfetamine—Dizziness—Paclitaxel—breast cancer	0.000162	0.000374	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—breast cancer	0.000162	0.000373	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—breast cancer	0.00016	0.000369	CcSEcCtD
Lisdexamfetamine—Urticaria—Capecitabine—breast cancer	0.00016	0.000369	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Capecitabine—breast cancer	0.000159	0.000367	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—breast cancer	0.000159	0.000367	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—breast cancer	0.000159	0.000366	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—breast cancer	0.000158	0.000364	CcSEcCtD
Lisdexamfetamine—Vomiting—Paclitaxel—breast cancer	0.000156	0.000359	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000155	0.000358	CcSEcCtD
Lisdexamfetamine—Rash—Paclitaxel—breast cancer	0.000155	0.000356	CcSEcCtD
Lisdexamfetamine—Dermatitis—Paclitaxel—breast cancer	0.000154	0.000356	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—breast cancer	0.000154	0.000356	CcSEcCtD
Lisdexamfetamine—Headache—Paclitaxel—breast cancer	0.000154	0.000354	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Docetaxel—breast cancer	0.000153	0.000353	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—breast cancer	0.000152	0.00035	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—breast cancer	0.00015	0.000345	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—breast cancer	0.00015	0.000345	CcSEcCtD
Lisdexamfetamine—Asthenia—Docetaxel—breast cancer	0.000149	0.000344	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—breast cancer	0.000149	0.000343	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—breast cancer	0.000148	0.000342	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Capecitabine—breast cancer	0.000148	0.000342	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—breast cancer	0.000147	0.000339	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—breast cancer	0.000146	0.000337	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—breast cancer	0.000146	0.000336	CcSEcCtD
Lisdexamfetamine—Nausea—Paclitaxel—breast cancer	0.000146	0.000336	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—breast cancer	0.000146	0.000335	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000145	0.000335	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—breast cancer	0.000145	0.000334	CcSEcCtD
Lisdexamfetamine—Asthenia—Capecitabine—breast cancer	0.000144	0.000333	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—breast cancer	0.000143	0.00033	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—breast cancer	0.000143	0.000329	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Docetaxel—breast cancer	0.000142	0.000328	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—breast cancer	0.00014	0.000324	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—breast cancer	0.00014	0.000323	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—breast cancer	0.000138	0.000317	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Capecitabine—breast cancer	0.000138	0.000317	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—breast cancer	0.000137	0.000317	CcSEcCtD
Lisdexamfetamine—Dizziness—Docetaxel—breast cancer	0.000137	0.000317	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—breast cancer	0.000137	0.000316	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—breast cancer	0.000137	0.000315	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—breast cancer	0.000136	0.000314	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—breast cancer	0.000136	0.000312	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—breast cancer	0.000135	0.000312	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—breast cancer	0.000135	0.000311	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000134	0.00031	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—breast cancer	0.000134	0.000308	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—breast cancer	0.000134	0.000308	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—breast cancer	0.000133	0.000307	CcSEcCtD
Lisdexamfetamine—Dizziness—Capecitabine—breast cancer	0.000133	0.000307	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—breast cancer	0.000132	0.000305	CcSEcCtD
Lisdexamfetamine—Vomiting—Docetaxel—breast cancer	0.000132	0.000305	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—breast cancer	0.000132	0.000304	CcSEcCtD
Lisdexamfetamine—Rash—Docetaxel—breast cancer	0.000131	0.000302	CcSEcCtD
Lisdexamfetamine—Dermatitis—Docetaxel—breast cancer	0.000131	0.000302	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—breast cancer	0.00013	0.0003	CcSEcCtD
Lisdexamfetamine—Headache—Docetaxel—breast cancer	0.00013	0.0003	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—breast cancer	0.00013	0.000299	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—breast cancer	0.000129	0.000298	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—breast cancer	0.000129	0.000298	CcSEcCtD
Lisdexamfetamine—Vomiting—Capecitabine—breast cancer	0.000128	0.000295	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—breast cancer	0.000127	0.000293	CcSEcCtD
Lisdexamfetamine—Rash—Capecitabine—breast cancer	0.000127	0.000292	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—breast cancer	0.000127	0.000292	CcSEcCtD
Lisdexamfetamine—Dermatitis—Capecitabine—breast cancer	0.000127	0.000292	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—breast cancer	0.000127	0.000292	CcSEcCtD
Lisdexamfetamine—Headache—Capecitabine—breast cancer	0.000126	0.000291	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—breast cancer	0.000126	0.00029	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—breast cancer	0.000125	0.000289	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—breast cancer	0.000125	0.000288	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—breast cancer	0.000125	0.000287	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—breast cancer	0.000124	0.000285	CcSEcCtD
Lisdexamfetamine—Nausea—Docetaxel—breast cancer	0.000123	0.000285	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—breast cancer	0.000123	0.000284	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—breast cancer	0.000122	0.000281	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—breast cancer	0.000121	0.000279	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—breast cancer	0.000121	0.000279	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—breast cancer	0.00012	0.000276	CcSEcCtD
Lisdexamfetamine—Nausea—Capecitabine—breast cancer	0.00012	0.000276	CcSEcCtD
Lisdexamfetamine—Urticaria—Methotrexate—breast cancer	0.000119	0.000274	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—breast cancer	0.000118	0.000273	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—breast cancer	0.000117	0.00027	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Doxorubicin—breast cancer	0.000116	0.000267	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—breast cancer	0.000115	0.000266	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—breast cancer	0.000114	0.000263	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Doxorubicin—breast cancer	0.000113	0.00026	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000112	0.000258	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—breast cancer	0.000112	0.000258	CcSEcCtD
Lisdexamfetamine—Urticaria—Epirubicin—breast cancer	0.000111	0.000257	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—breast cancer	0.000111	0.000256	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—breast cancer	0.000111	0.000255	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—breast cancer	0.00011	0.000254	CcSEcCtD
Lisdexamfetamine—Asthenia—Methotrexate—breast cancer	0.000107	0.000248	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Epirubicin—breast cancer	0.000103	0.000238	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—breast cancer	0.000103	0.000238	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—breast cancer	0.000103	0.000236	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—breast cancer	0.000102	0.000236	CcSEcCtD
Lisdexamfetamine—Asthenia—Epirubicin—breast cancer	0.000101	0.000232	CcSEcCtD
Lisdexamfetamine—Dizziness—Methotrexate—breast cancer	9.91e-05	0.000228	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Epirubicin—breast cancer	9.59e-05	0.000221	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—breast cancer	9.56e-05	0.00022	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—breast cancer	9.52e-05	0.00022	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—breast cancer	9.45e-05	0.000218	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—breast cancer	9.44e-05	0.000218	CcSEcCtD
Lisdexamfetamine—Headache—Methotrexate—breast cancer	9.38e-05	0.000216	CcSEcCtD
Lisdexamfetamine—Asthenia—Doxorubicin—breast cancer	9.31e-05	0.000215	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—breast cancer	9.27e-05	0.000214	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL3—breast cancer	8.94e-05	0.000734	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL27—breast cancer	8.94e-05	0.000734	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Epirubicin—breast cancer	8.91e-05	0.000205	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—breast cancer	8.9e-05	0.000205	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—breast cancer	8.89e-05	0.000729	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Doxorubicin—breast cancer	8.88e-05	0.000205	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—NCOA2—breast cancer	8.84e-05	0.000725	CbGpPWpGaD
Lisdexamfetamine—Rash—Epirubicin—breast cancer	8.84e-05	0.000204	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—breast cancer	8.83e-05	0.000204	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—breast cancer	8.78e-05	0.000202	CcSEcCtD
Lisdexamfetamine—Dizziness—Doxorubicin—breast cancer	8.58e-05	0.000198	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—breast cancer	8.43e-05	0.000692	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CALCA—breast cancer	8.41e-05	0.00069	CbGpPWpGaD
Lisdexamfetamine—Nausea—Epirubicin—breast cancer	8.33e-05	0.000192	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—breast cancer	8.25e-05	0.00019	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—breast cancer	8.24e-05	0.000676	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL12—breast cancer	8.21e-05	0.000674	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCR4—breast cancer	8.21e-05	0.000674	CbGpPWpGaD
Lisdexamfetamine—Rash—Doxorubicin—breast cancer	8.18e-05	0.000189	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—breast cancer	8.17e-05	0.000188	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—breast cancer	8.15e-05	0.000668	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TFRC—breast cancer	8.14e-05	0.000668	CbGpPWpGaD
Lisdexamfetamine—Headache—Doxorubicin—breast cancer	8.13e-05	0.000187	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—breast cancer	7.95e-05	0.000652	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—breast cancer	7.92e-05	0.00065	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MDM2—breast cancer	7.85e-05	0.000644	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—NCOA2—breast cancer	7.83e-05	0.000643	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—breast cancer	7.82e-05	0.000642	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—breast cancer	7.76e-05	0.000637	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—breast cancer	7.71e-05	0.000178	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—breast cancer	7.47e-05	0.000613	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—NCOA1—breast cancer	7.45e-05	0.000611	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AGTR1—breast cancer	7.43e-05	0.000609	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PLG—breast cancer	7.26e-05	0.000596	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—breast cancer	7.23e-05	0.000593	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—breast cancer	7.22e-05	0.000592	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RGS2—breast cancer	7.2e-05	0.000591	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BRAF—breast cancer	7.18e-05	0.000589	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCL20—breast cancer	7.12e-05	0.000584	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—breast cancer	7.04e-05	0.000577	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—breast cancer	7.01e-05	0.000575	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCDC88C—breast cancer	6.97e-05	0.000572	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LGR6—breast cancer	6.97e-05	0.000572	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—LPAR1—breast cancer	6.9e-05	0.000566	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—breast cancer	6.7e-05	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SFRP1—breast cancer	6.65e-05	0.000546	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GPER1—breast cancer	6.65e-05	0.000546	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—NCOA1—breast cancer	6.6e-05	0.000541	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RGS2—breast cancer	6.54e-05	0.000537	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PDE4D—breast cancer	6.51e-05	0.000534	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL20—breast cancer	6.47e-05	0.000531	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—breast cancer	6.43e-05	0.000528	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PLG—breast cancer	6.43e-05	0.000528	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—breast cancer	6.43e-05	0.000528	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NMBR—breast cancer	6.38e-05	0.000523	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CNR2—breast cancer	6.35e-05	0.000521	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—LPAR1—breast cancer	6.26e-05	0.000514	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MDM2—breast cancer	6.02e-05	0.000494	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—RAF1—breast cancer	5.99e-05	0.000492	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—breast cancer	5.98e-05	0.000491	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—breast cancer	5.94e-05	0.000487	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTGER1—breast cancer	5.93e-05	0.000486	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEYL—breast cancer	5.93e-05	0.000486	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CUL5—breast cancer	5.93e-05	0.000486	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PDE4D—breast cancer	5.91e-05	0.000485	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CNR2—breast cancer	5.76e-05	0.000473	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—breast cancer	5.7e-05	0.000467	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RSPO3—breast cancer	5.57e-05	0.000457	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—breast cancer	5.54e-05	0.000454	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL2—breast cancer	5.46e-05	0.000448	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGTR2—breast cancer	5.46e-05	0.000448	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WNT10B—breast cancer	5.42e-05	0.000445	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WWOX—breast cancer	5.42e-05	0.000445	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—WNT1—breast cancer	5.42e-05	0.000445	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—breast cancer	5.41e-05	0.000444	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTHLH—breast cancer	5.4e-05	0.000443	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INHBB—breast cancer	5.28e-05	0.000433	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL3—breast cancer	5.28e-05	0.000433	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL27—breast cancer	5.28e-05	0.000433	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDE2A—breast cancer	5.28e-05	0.000433	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDNRB—breast cancer	5.23e-05	0.000429	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BMPR2—breast cancer	5.04e-05	0.000414	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DLL4—breast cancer	5.04e-05	0.000414	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL2—breast cancer	4.96e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGTR2—breast cancer	4.96e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTHLH—breast cancer	4.9e-05	0.000402	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDH5—breast cancer	4.83e-05	0.000396	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CALCA—breast cancer	4.75e-05	0.00039	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDNRB—breast cancer	4.75e-05	0.000389	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SFRP2—breast cancer	4.74e-05	0.000389	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRLR—breast cancer	4.65e-05	0.000382	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR4—breast cancer	4.64e-05	0.000381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL12—breast cancer	4.64e-05	0.000381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—breast cancer	4.64e-05	0.00038	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLI2—breast cancer	4.49e-05	0.000369	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VCP—breast cancer	4.49e-05	0.000369	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	4.47e-05	0.000367	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEPR—breast cancer	4.42e-05	0.000363	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—breast cancer	4.41e-05	0.000362	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CALCA—breast cancer	4.31e-05	0.000354	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—breast cancer	4.31e-05	0.000353	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—breast cancer	4.28e-05	0.000351	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL12—breast cancer	4.21e-05	0.000346	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR4—breast cancer	4.21e-05	0.000346	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGTR1—breast cancer	4.2e-05	0.000344	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	4.17e-05	0.000342	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ARHGDIA—breast cancer	4.11e-05	0.000337	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—breast cancer	4.02e-05	0.00033	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FST—breast cancer	4e-05	0.000329	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEY2—breast cancer	3.95e-05	0.000324	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RPS6KB2—breast cancer	3.91e-05	0.000321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RGS2—breast cancer	3.86e-05	0.000317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	3.83e-05	0.000314	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL20—breast cancer	3.82e-05	0.000313	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGTR1—breast cancer	3.81e-05	0.000313	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ITPR1—breast cancer	3.77e-05	0.000309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPAR1—breast cancer	3.7e-05	0.000304	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TLE3—breast cancer	3.7e-05	0.000304	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEY1—breast cancer	3.66e-05	0.0003	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—breast cancer	3.64e-05	0.000298	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DLL1—breast cancer	3.59e-05	0.000295	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—breast cancer	3.56e-05	0.000292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	3.54e-05	0.000291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIST1H2BK—breast cancer	3.53e-05	0.000289	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIST1H2BC—breast cancer	3.53e-05	0.000289	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRB7—breast cancer	3.49e-05	0.000287	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDE4D—breast cancer	3.49e-05	0.000287	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CSF2—breast cancer	3.48e-05	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TAB2—breast cancer	3.43e-05	0.000282	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ITPR1—breast cancer	3.42e-05	0.000281	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CNR2—breast cancer	3.4e-05	0.000279	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—breast cancer	3.4e-05	0.000279	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MMP3—breast cancer	3.4e-05	0.000279	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	3.39e-05	0.000278	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DKK1—breast cancer	3.32e-05	0.000273	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—breast cancer	3.3e-05	0.000271	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFC—breast cancer	3.3e-05	0.000271	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAG2—breast cancer	3.25e-05	0.000266	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—breast cancer	3.22e-05	0.000264	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WNT1—breast cancer	3.2e-05	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PLA2G4A—breast cancer	3.19e-05	0.000262	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CSF2—breast cancer	3.16e-05	0.000259	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH4—breast cancer	3.03e-05	0.000249	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GZMB—breast cancer	3.02e-05	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL2—breast cancer	2.93e-05	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGTR2—breast cancer	2.93e-05	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTHLH—breast cancer	2.89e-05	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BMP2—breast cancer	2.89e-05	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDNRB—breast cancer	2.8e-05	0.00023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PGR—breast cancer	2.78e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—THBS1—breast cancer	2.76e-05	0.000227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FLT1—breast cancer	2.64e-05	0.000216	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF3—breast cancer	2.62e-05	0.000215	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SQSTM1—breast cancer	2.62e-05	0.000215	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—breast cancer	2.61e-05	0.000214	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAG1—breast cancer	2.59e-05	0.000213	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH3—breast cancer	2.58e-05	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PARP1—breast cancer	2.58e-05	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CALCA—breast cancer	2.55e-05	0.000209	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RPS6—breast cancer	2.52e-05	0.000207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF4—breast cancer	2.5e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR4—breast cancer	2.49e-05	0.000204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL12—breast cancer	2.49e-05	0.000204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PAK1—breast cancer	2.44e-05	0.0002	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TCF7L2—breast cancer	2.4e-05	0.000197	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT2—breast cancer	2.39e-05	0.000196	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—breast cancer	2.37e-05	0.000195	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSP90AA1—breast cancer	2.31e-05	0.00019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH2—breast cancer	2.31e-05	0.00019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—breast cancer	2.3e-05	0.000188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGTR1—breast cancer	2.25e-05	0.000185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRL—breast cancer	2.25e-05	0.000185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STK11—breast cancer	2.22e-05	0.000182	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADAM10—breast cancer	2.22e-05	0.000182	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLG—breast cancer	2.19e-05	0.00018	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT2—breast cancer	2.17e-05	0.000178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF10—breast cancer	2.16e-05	0.000177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—breast cancer	2.08e-05	0.000171	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFA—breast cancer	2.08e-05	0.000171	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFBR2—breast cancer	2.05e-05	0.000168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ITPR1—breast cancer	2.02e-05	0.000166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB4—breast cancer	2.01e-05	0.000165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT5A—breast cancer	2.01e-05	0.000165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP3—breast cancer	2.01e-05	0.000165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—breast cancer	2e-05	0.000164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMAD4—breast cancer	1.94e-05	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1R—breast cancer	1.93e-05	0.000158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—breast cancer	1.92e-05	0.000158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES1—breast cancer	1.9e-05	0.000156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLA2G4A—breast cancer	1.89e-05	0.000155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCOR1—breast cancer	1.89e-05	0.000155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CSF2—breast cancer	1.87e-05	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF1—breast cancer	1.87e-05	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAF1—breast cancer	1.86e-05	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRG1—breast cancer	1.85e-05	0.000152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—H2AFX—breast cancer	1.84e-05	0.000151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—breast cancer	1.84e-05	0.000151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—E2F1—breast cancer	1.83e-05	0.00015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—breast cancer	1.82e-05	0.000149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SPP1—breast cancer	1.75e-05	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—breast cancer	1.75e-05	0.000143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB3—breast cancer	1.73e-05	0.000142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR2—breast cancer	1.73e-05	0.000142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—breast cancer	1.67e-05	0.000137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—breast cancer	1.66e-05	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR1—breast cancer	1.61e-05	0.000132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—breast cancer	1.59e-05	0.00013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEP—breast cancer	1.55e-05	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—breast cancer	1.54e-05	0.000126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—breast cancer	1.52e-05	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ESR1—breast cancer	1.48e-05	0.000122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FN1—breast cancer	1.46e-05	0.00012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NFKBIA—breast cancer	1.45e-05	0.000119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH1—breast cancer	1.43e-05	0.000118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—breast cancer	1.4e-05	0.000115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KIT—breast cancer	1.4e-05	0.000115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—breast cancer	1.4e-05	0.000115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGF—breast cancer	1.38e-05	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK3—breast cancer	1.34e-05	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRAF—breast cancer	1.32e-05	0.000108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—breast cancer	1.28e-05	0.000105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT2—breast cancer	1.28e-05	0.000105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—breast cancer	1.28e-05	0.000105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—breast cancer	1.23e-05	0.000101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—breast cancer	1.22e-05	0.0001	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—breast cancer	1.22e-05	9.99e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—breast cancer	1.21e-05	9.89e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—breast cancer	1.16e-05	9.54e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—breast cancer	1.11e-05	9.09e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MDM2—breast cancer	1.1e-05	9.05e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAF1—breast cancer	1.1e-05	9.02e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RELA—breast cancer	1.09e-05	8.98e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—breast cancer	1.09e-05	8.92e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—breast cancer	1.07e-05	8.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—breast cancer	1.07e-05	8.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—breast cancer	1.03e-05	8.46e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—breast cancer	1.02e-05	8.41e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—breast cancer	1.01e-05	8.26e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—breast cancer	9.96e-06	8.18e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—breast cancer	9.87e-06	8.1e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—breast cancer	9.86e-06	8.09e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—breast cancer	9.81e-06	8.05e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—breast cancer	9.61e-06	7.88e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUN—breast cancer	9.59e-06	7.87e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—breast cancer	9.52e-06	7.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—breast cancer	9.33e-06	7.65e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	9.3e-06	7.63e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—breast cancer	9.28e-06	7.61e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK8—breast cancer	9.07e-06	7.44e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—breast cancer	9.05e-06	7.42e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SRC—breast cancer	8.6e-06	7.06e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—breast cancer	8.38e-06	6.87e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—breast cancer	8.3e-06	6.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK3—breast cancer	7.93e-06	6.5e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—breast cancer	7.71e-06	6.32e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—breast cancer	7.69e-06	6.31e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—breast cancer	7.54e-06	6.19e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—breast cancer	7.12e-06	5.84e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	6.54e-06	5.37e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—breast cancer	6.33e-06	5.19e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—breast cancer	6.05e-06	4.97e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—breast cancer	5.79e-06	4.75e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—breast cancer	5.35e-06	4.39e-05	CbGpPWpGaD
